Key result
Ghrelin blunts GH peak by ~97% in hypothalamic lesion patients vs controls, indicating hypothalamic action.
Why the study?
The site of ghrelin action on growth hormone secretion, whether at the pituitary or hypothalamic level, was not known.
Does ghrelin stimulate GH release at the hypothalamic or pituitary level in patients with organic hypothalamic lesions?
Case-Control
Does ghrelin stimulate GH release at the hypothalamic or pituitary level in patients with organic hypothalamic lesions?
Absolute Event Rate: 2% vs 75.1%
Ghrelin's main action on growth hormone release is exerted at the hypothalamic level, suggesting it lacks clinical utility in patients with GH deficiency due to organic hypothalamic lesions.
Ghrelin may lack utility in hypothalamic GH deficiency; supports hypothalamic site of action but leaves open pituitary effects.
Ghrelin, a recently isolated hormone, seems to participate in the physiological regulation of GH secretion. Exogenously administered ghrelin stimulates GH discharge in all species so far tested including man, but whether this action is exerted at pituitary or alternatively at hypothalamic level is not known at present. To understand the point of ghrelin action a group of patients with organic lesion mainly in the hypothalamic area and matched controls were studied. Patients showed a severe GH deficiency after hypothalamic stimulation (ITT), but partial response after GHRH administration. Cases and controls were tested on three separate days by either ghrelin; GHRH; and ghrelin plus GHRH; always at 1 micro g/Kg iv. The mean GH peak after stimulation in the patients were: 0.4 +/- 0.1 micro g/L by ITT; 3.1 +/- 0.5 micro g/L after GHRH; 2.0 +/- 0.8 micro g/L after ghrelin; and 9.6 +/- 2.9 micro g/L after the combination of GHRH plus ghrelin. In the controls GHRH induced a GH peak of 21.2 +/- 7.5 micro g/L, and 75.1 +/- 16.0 micro g/L after ghrelin with a peak after GHRH + ghrelin of 103.5 +/- 26.4 micro g/L. These data indicate that when hypothalamic structures are not operative ghrelin, either alone or in combination with GHRH, is not able to significantly release GH. In addition to postulating a hypothalamic point of action for the ghrelin-induced GH secretion, these results suggests that ghrelin will not have significant clinical utility in patients with GH deficiency due to organic lesion.
No takes yet. Share an insight, caveat, or question.
Popović et al. (2003) conducted a case-control in Organic lesion in the hypothalamic area with GH deficiency. Ghrelin vs. Matched controls was evaluated on Mean GH peak after stimulation. Ghrelin administration in patients with hypothalamic lesions resulted in a blunted mean GH peak compared to matched controls (2.0 vs 75.1 micro g/L), indicating a hypothalamic site of action.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: